文献速递炎症性肠病

对诱导治疗未达临床应答的克罗恩病患者延长瑞莎珠单抗治疗

Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-02-03

评估中重度克罗恩病患者经12周瑞莎珠单抗静脉诱导未达临床应答后,延长治疗(1200mg静脉或180mg/360mg皮下)的疗效与安全性。多数初始无应答者在第24周达到临床应答,皮下360mg疗效数值上优于180mg,延长治疗耐受良好。

要点

  • 初始无应答者延长治疗至第24周,临床应答率76.2%(180mg皮下)、63.7%(360mg皮下)、62.3%(1200mg静脉)。
  • 第24周临床缓解率分别为43.0%、45.1%、22.1%,内镜应答率32.4%、32.5%、40.5%。
  • 皮下延迟应答者继续治疗至FORTIFY第52周,临床应答率56.7%(180mg)和69.7%(360mg)。

核心结论

  • 多数静脉瑞莎珠单抗诱导初始无应答者接受12周延长治疗后,第24周临床和内镜结局改善。
  • 接受皮下瑞莎珠单抗延长治疗的延迟应答者,其改善在FORTIFY研究中得以维持。
  • 延长治疗耐受良好,未发现新的安全风险。

研究设计与样本

  • 对静脉瑞莎珠单抗诱导(600mg或1200mg,第0、4、8周)未达临床应答的初始无应答者,按1:1:1重新随机接受延长盲法治疗:1200mg静脉(第12、16、20周)或180mg/360mg皮下(第12、20周)。
  • 第24周对皮下瑞莎珠单抗达临床应答的延迟应答者,在FORTIFY研究中继续原剂量治疗。
  • 评估临床、内镜和安全性结局。

主要发现

  • 第24周临床应答率:180mg皮下76.2%,360mg皮下63.7%,1200mg静脉62.3%。
  • 第24周临床缓解率:180mg皮下43.0%,360mg皮下45.1%,1200mg静脉22.1%。
  • 第24周内镜应答率:180mg皮下32.4%,360mg皮下32.5%,1200mg静脉40.5%;内镜缓解率分别为25.1%、18.0%、23.5%。
  • FORTIFY第52周,皮下延迟应答者临床应答率56.7%(180mg)和69.7%(360mg),临床缓解率43.3%和54.5%,内镜应答率36.7%和45.5%,内镜缓解率40.0%和42.4%。
  • 皮下360mg与180mg相比,疗效数值上普遍更优。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The efficacy and safety of extended treatment with risankizumab (RZB), an anti-interleukin-23 p19 monoclonal antibody, were evaluated in patients with moderate to severe Crohn's disease (CD) who did not achieve clinical response to 12 weeks (W) RZB induction treatment ('initial nonresponders'). METHODS: Initial nonresponders to intravenous (IV) RZB induction (600 mg or 1200 mg at W0, W4, and W8) were rerandomized 1:1:1 to receive extended blinded RZB treatment (1200 mg IV at W12, W16, and W20, or subcutaneous [SC] 180 mg or 360 mg at W12 and W20). Patients with clinical response to SC RZB at W24 ('delayed responders') continued their dose in FORTIFY. Clinical, endoscopic, and safety outcomes were evaluated. RESULTS: Most initial nonresponders achieved stool frequency (SF)/ abdominal pain score (APS) clinical response by W24 (76.2% [180 mg SC], 63.7% [360 mg SC], 62.3% [1200 mg IV]), whereas a subset also achieved W24 SF/APS clinical remission (43.0%, 45.1%, and 22.1%), endoscopic response (32.4%, 32.5%, and 40.5%), and endoscopic remission (25.1%, 18.0%, and 23.5%). Most delayed responders to SC RZB continued to demonstrate clinical response at FORTIFY W52 (56.7% [180 mg SC], 69.7% [360 mg SC]), along with SF/APS clinical remission (43.3% and 54.5%), endoscopic response (36.7% and 45.5%), and endoscopic remission (40.0% and 42.4%). Numerically greater efficacy was generally observed with 360 mg SC vs 180 mg SC. The safety profile of extended treatment was consistent with previously reported trials. CONCLUSIONS: Most initial nonresponders to IV RZB induction who received 12W of extended RZB treatment demonstrated improved clinical and endoscopic outcomes at W24. Improvements in patients who received SC RZB extended treatment were maintained during FORTIFY. Extended treatment was well tolerated with no new safety risks identified. CLINICALTRIALS: gov: MOTIVATE (Number: NCT03104413), ADVANCE (Number: NCT03105128), and FORTIFY (Number: NCT03105102).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Panaccione R, Ferrante M, Dotan I, et al. Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment. Clin Gastroenterol Hepatol. 2025. PMID: 39909280. doi:10.1016/j.cgh.2024.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。